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Introduction
Seven risk factors account for 56.1% of
the attributable disability-adjusted life
years (DALYs) in western Europe: dietary
risks, smoking, high blood pressure, high
body mass index (BMI), physical inactivity,
excessive alcohol consumption, and high
fasting plasma glucose [1]. Although such
a figure reflects the predominant burden
of noncommunicable diseases (NCDs) in
high-income countries, it is becoming a
priority also in middle-income and low-
income countries [2]. By addressing such
risk factors, prevention and health promo-
tion can play a major role in reducing the
burden of NCDs. The crucial function of
prevention in tackling the NCDs epidemic
is shared globally, as highlighted by the
WHO programme ‘‘Gaining Health’’ and,
more recently, by the United Nations
High-Level Meeting on NCDs—in which
prevention has been included among the
five priority actions needed globally and
nationally to respond to the NCDs epi-
demic [3,4].
What distinguishes prevention of NCDs
from the more traditional prevention
activities of communicable diseases is the
aim to avoid or change health-compro-
mising behaviours or to promote healthy
behaviours. Prevention of NCDs includes
individual and environmental interven-
tion, e.g., family-based interventions tack-
ling alcohol misuse, national policies
prohibiting indoor smoking, school-based
education to foster correct eating behav-
iour, walking groups for children or adults,
taxation of tobacco or alcohol products,
and policies to limit junk food in vending
machines on school premises. This aim is
particularly critical and requires much
more caution than traditional prevention
practices, for example, those intended to
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Summary Points
N Prevention interventions tackling health-compromising behaviours have the
potential to play a major role in reducing the burden of noncommunicable
diseases in Europe and other areas of the world. However, in Europe, no prior
evaluation is required for the implementation of prevention interventions, thus
leading to widespread dissemination of potentially ineffective or harmful
interventions.
N A central, transparent, evidence-based, context-aware, and research-oriented
approval process for behavioural prevention interventions is likely to foster the
implementation and dissemination of effective interventions in Europe.
N Similarly to medicine approval systems, such a new approval process could be
based on four consequential phases evaluating the effect of the following:
single components (phase 1); combinations of components (phase 2); the final
intervention—comprising only components found effective in the previous
phases—via large, multicentre, randomized trials whenever possible (phase 3);
and the long-term effects as well as the effects in different contexts (phase 4).
N Once phase 3 shows convincing results, the intervention would be approved for
delivery to its target population.
N An approval process for behavioural prevention interventions is likely to lead to
positive consequences both for practice, by strengthening the role and impact
of prevention in times of limited economic resources, and for research, by
promoting the robust evaluation of all promising prevention interventions.
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control environmental pollution and in-
fectious diseases.
In Europe, a number of official docu-
ments, both at the regional and country
level, promote an evidence-based ap-
proach to prevention [3,5,6]. However,
there is no regulatory system for the
implementation of behavioural prevention
interventions. This contrasts with the
situation in clinical medicine, in which
there is a long-standing culture of using
robust evidence to inform commissioning
and clinical decisions. The European
Medicines Agency (EMA) and European
national authorities manage a well-estab-
lished, although not perfect [7], system for
the assessment of safety and effectiveness
of drugs.
With this contribution, we aim to
initiate a debate about the need for a
unique European evaluation and approval
system of prevention interventions for
health-compromising behaviours.
Need for a Rigorous Evaluation
of Behavioural Prevention
Interventions
In Europe, interventions for preventing
health-compromising behaviours can be
implemented and disseminated without
any preliminary authorisation, whatever
setting (school, family, and community),
professional, or type of method and
technology involved. This is of concern
for both ethical and economic reasons.
First—and contrary to common belief—
prevention interventions are not just
harmless or ineffective in the worst-case
scenario. They may also be harmful.
Iatrogenic effects have been observed in
interventions tackling risky behaviours
such as physical inactivity, substance
misuse, early sexual intercourse, and
juvenile delinquency [8–12]. It is ethically
unacceptable that a prevention interven-
tion could significantly increase BMI, or
tobacco or alcohol use, or frequency of
cannabis use, or pregnancies and sexually
transmitted diseases. Quoting the ‘‘father’’
of evidence-based medicine, David Sack-
ett, ‘‘[…] the presumption that justifies the
aggressive assertiveness with which we go
after the unsuspecting healthy must be
based on the highest level of randomized
evidence that our preventive manoeuvre
will, in fact, do more good than harm’’
[13].
Second, resources are likely to be
wasted if evidence of effectiveness is
missing or not sought. Cochrane reviews
on the prevention of risky behaviours [14–
16] show that effective interventions are in
the minority of those evaluated by ran-
domized studies. There is no reason to
presume that non-evaluated interventions
may be more effective than those that
underwent rigorous evaluation. The re-
source allocation in the development and
delivery of ineffective interventions is of
particular concern in these times, given
Europe’s overstretched health systems.
Need for Improving the
Analysis and Description of
Mechanisms of Behavioural
Prevention Interventions
Prevention interventions for health-
compromising behaviours usually target
psychological, social, and organisational
factors hypothesised to mediate the asso-
ciations between intervention and behav-
ioural outcomes. Although theories should
play a crucial role in the design and
evaluation of prevention interventions,
there is a lack of awareness and consensus
as to which theories should be applied and
what method should be used [17,18].
Many interventions are an amalgam of
approaches and contents that do not
explicitly draw on formal theories; others
mention theory but are not truly theory-
driven and do not always adhere consis-
tently to a theory’s tenets, being driven by
implicit common sense models of behav-
iour [19,20].
Moreover, interventions are usually
delivered as a complex combination of
components (‘‘active ingredients’’ target-
ing different mediators), both in terms of
contents, activities, techniques, and modes
of delivery. However, the interventions are
usually poorly described. Less than 30% of
reports of randomized studies present a
detailed description of the intervention
allowing accurate replication and imple-
mentation, and fewer include descriptions
of mechanisms of action [19,21]. In
addition, complex interventions, com-
posed of several components, are usually
evaluated together in randomized studies,
which makes it difficult to disentangle the
effect of a single ingredient on mediators
and behavioural outcomes. The failure to
conceptualize, define, and describe inter-
vention components and mediators re-
stricts the potential for evaluation to add
evidence about effective interventions and
mechanisms of action. In addition, the
effects of context are rarely recognized,
reported, or analysed.
Not knowing why, how, and where
prevention interventions work limits knowl-
edge about generalizability and optimiza-
tion of interventions. It also increases the
cost of implementation, as non-essential
mediators might be inappropriately tar-
geted and non-essential components may
be inadvertently included.
If mediators of the target behaviour are
identified, it is easier to design intervention
components that are more likely to be
effective. If the intervention components
most strongly associated with effectiveness
are known, more accessible, practical, and
lower-cost, yet still effective, prevention
interventions can be elaborated and dis-
seminated. Moreover, they can be adapted
to meet local needs and implemented in
situations that are less ideal than research
circumstances.
The complexity of behavioural preven-
tion interventions, together with the lack
of accurate reporting of mechanisms of
action and analysis of the effects of
components and their interactions, has
serious consequences for prevention sci-
ence: new interventions and evaluations
occur in relative isolation, limiting the
possibility of building an incremental
technology of prevention [19].
Identifying and Selecting
Evidence-Based Behavioural
Prevention Interventions:
Current Situation
Prevention guidelines are uncommon
and usually of mixed quality, and no
national or international systems exist for
the regulation of effective interventions.
Prevention professionals usually have to
search and appraise the literature by
themselves if they want to select evi-
dence-based interventions to transfer into
practice.
There are some local experiences of
public registries of evidence-based inter-
ventions in some areas of prevention [22–
24]. However, at least two reasons suggest
that these registries may not be enough to
guide practice. First, they have a weak
level of global authority; thus, they cannot
limit the proliferation of unevaluated or
harmful interventions. Secondly, they
present a great variability in the level of
evidence required to define an interven-
tion as effective, and in the way they help
dissemination. This is obviously a potential
cause of uncertainty for decision-makers
and implementers. Table 1 compares the
criteria for intervention classification
adopted by seven registries considered by
Gandhi et al. [22], to which we added two
European resources, the European Mon-
itoring Centre for Drugs and Drug Abuse
(EMCDDA) ’s Best Practice Portal and the
Dutch Recognition System [23,24]. Al-
though evidence of efficacy and quality of
evaluation are considered by all registries,
aspects such as quality of programme
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contents, programme implementation
methods, and programme replicability
are considered only in four out of nine
registries. In this panorama the attempts to
define standards of quality of prevention
intervention, for example, from the Soci-
ety for Prevention Research (see at www.
preventionresearch.org) and from the
EMCDDA (see at www.emcdda.europa.
eu), do not appear to have had any visible
effects.
Existing Frameworks for the
Regulation of Interventions
Improving the regulation of prevention
interventions for health-compromising be-
haviours to ensure that effective interven-
tions are implemented and disseminated is
likely to be challenging.
In clinical practice, authorization agen-
cies such as the United States Food and
Drug Administration (FDA) and the Eu-
ropean Medicine Agency (EMA) are
appointed to manage an evidence-based
evaluation process intended to guarantee
that only safe and effective drugs will be
approved for marketing. Although formal
pathways are slightly different, for both
agencies the process is based on a four-step
evaluation: small trials to test pharmaco-
dynamics, pharmacokinetics, and dosage
(phase 1); medium trials for assessing
efficacy and short-term effects (phase 2);
large, randomized trials to evaluate effec-
tiveness and side effects (phase 3); and
post-marketing surveillance and additional
studies for specific subgroups of patients
and assessment of rare side effects (phase
4) [25]. Pharmaceutical companies apply
for EMA and/or FDA approval by
transmitting all the preclinical and clinical
information obtained during the first three
phases [26]. Approval is a necessary
prerequisite for marketing a drug in
Europe and in the United States.
A systematic approach to developing
and evaluating complex prevention inter-
ventions, as the majority of prevention
interventions are, has been developed by
the United Kingdom’s Medical Research
Council (MRC) [27,28]. The first set of
guidance proposed a process for the
evaluation of complex interventions,
which is logically consistent with the
sequential phases of the drug approval
process. The second set was based on a
more sophisticated understanding of com-
plexity and called for the defining of
relevant intervention components, as well
as underlying mechanisms and theories
(modelling phase), testing acceptability
and feasibility (pilot phase), evaluating
effectiveness in an experimental study
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(evaluation phase), and assessing long-term
effects in uncontrolled settings (implemen-
tation phase). The updated guidance in
2008 conceptualised the process as a cycle,
emphasising the importance of considering
implementation right at the beginning of
the intervention development process.
Collins and colleagues addressed anoth-
er issue that is not shared by drug
registration systems: the complexity of
interventions [29,30]. In order to evaluate
the role of each single component of
prevention interventions, they suggest
adopting a multiphase optimization strat-
egy, which may involve the application of
a factorial design in order to assess the
independent role of each component (see
at http://methodology.psu.edu/ra/most).
These approaches, no matter how
innovative, however, are not applicable
to policy evaluation, a strong component
of preventive strategies. In order to keep
the same level of validity of the assessment,
this requires tailored approaches to eval-
uation [31], as those developed for tobac-
co control [32].
A Proposal for a System of
Evaluation and Approval of
Behavioural Prevention
Interventions
To tackle the overuse of interventions
without scientific evidence and the under-
use of effective interventions, Europe
needs an approval system for prevention
of health-compromising behaviours. This
system would allow decision-makers and
implementers to access the necessary
information and materials to select the
best prevention intervention for any spe-
cific need (e.g., target behaviour, popula-
tion, setting, available resources, etc.). This
system should be:
N Based on evidence. It should rely on
the most valid evaluation approach for
the specific intervention to assess. If
randomized controlled trial would not
be a feasible option, for example, for
policy evaluation, the system should
include alternative research designs
that allow for relatively strong causal
inferences (e.g., cohort design or inter-
rupted time series design).
N Aware of context. Contextual moder-
ators are of great importance for
prevention of health-compromising
behaviours and should be an essential
part of the evaluation, as they may
explain variations of effects across
different contexts. They can help to
describe how prevention interventions
work and should be accurately
identified and reported. Moreover,
replications of evaluation studies in
different contexts should be promoted
and considered as an element of
quality.
N Research-oriented. It should require
an accurate reporting of underpinning
theories, contents, mechanisms of ac-
tion, and effects of single components
on target behaviours to support the
advancement of prevention science.
N Transparent and open access. All steps
of evaluation should be transparently
reported; descriptive information and
complete data about evidence, bene-
fits, risks, and variations related to
different populations and contexts
should be publicly available. The level
of descriptive information must be
sufficient to allow replications across
different contexts with a high level of
fidelity.
N Based on international cooperation.
An international consensus on stan-
dards for releasing the certification of
effectiveness is required to ensure
widespread acceptance of this system
in the scientific community. Therefore,
a collaborative action of an extensive
range of researchers, policy-makers,
and health professionals is needed, as
well as an extraordinary effort and
mobilisation of resources.
In light of existing experiences, and
taking into account the key characteristics
described above, a four-phase evaluation
and approval process could be proposed
(Figure 1):
N Phase 1 should be aimed at evaluating
the effect of single components on
mediators and short-term outcomes
through experimental or observational
studies. This phase should also assess
dosage features (e.g., delivery frequen-
cy, duration, etc.) and other delivery
characteristics such as the appropriate
age group.
N Phase 2 should be aimed at evaluating
the effect of combinations of single
components which passed phase 1 on
short-term outcomes in the target
population through a pilot experimen-
tal study.
N Phase 3 should be aimed at evaluating
the effectiveness of the whole interven-
tion, once individual components have
shown evidence of effectiveness on
short- and medium-term outcomes in
phase 2. Whenever possible, an ade-
quately powered, randomized, con-
trolled design should be used to
allocate individuals or target groups
(e.g., schools, families) to study arms.
But, since environmental interventions
can hardly be evaluated by a random-
ized study, and they constitute a
cornerstone of any comprehensive
prevention strategy, such as smoking
bans or taxation of sugar-sweetened
beverage, they should be assessed with
other studies of high validity, as for
example, cohort studies or interrupted
time series.
N Interventions found to be effective in
this phase should be approved for
implementation and dissemination.
N Phase 4 should be aimed at evaluating
the effectiveness of approved interven-
Figure 1. Proposal for a four-step evaluation and approval process of prevention
interventions for health-compromising behaviours.
doi:10.1371/journal.pmed.1001740.g001
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tion in real-world settings (e.g., when
delivered by a school team rather than
a research team), the sustainability of
effects on outcomes over a longer
period of time and the long-term
safety, and the replicability of effects
on outcomes in different sociocultural
contexts and populations, for which an
adapted version of the intervention is
usually needed.
Such a centralized system could be
managed by a new public body, similar to
the European Medicines Agency (EMA).
Alternatively, an extended mandate to
carry out such a process could be given to
an existing and recognized public interna-
tional agency or organization or to a
network of research institutions coordinat-
ed by an international agency. The struc-
tural dimension of the proposed system
cannot be easily estimated, but would be
small. To make a rough estimation, an
elaboration from the Cochrane Library can
be of help: in 2012 the Library contained
altogether 30 systematic reviews on primary
prevention interventions; out of 503 inter-
ventions evaluated, only 171 (34.0%)
showed at least one outcome favouring
intervention [33]. Since Cochrane Li-
brary covers studies published in the last
several decades and only studies showing
positive results are expected to be
submitted to such an approval process,
these data suggest a few dozen interven-
tions to be reviewed per year.
The funding requirements are a critical
point: the amount depends too much on
the ambition of the project, and cannot be
estimated, even crudely. In any case, in
analogy with a scientific journal, all the
processes could be managed by a central
editorial unit, supported by a network of
referees, which would considerably con-
tain costs.
Once an intervention has been ap-
proved, it should be included in a
repository of effective interventions.
The system would provide all needed
materials and contacts with developers
and trainers, together with the necessary
information to select the intervention
fitting the prevention needs (such as
target behaviour, population, and set-
ting), and contextual constraints (e.g.,
availability of human resources, time,
and funding) of practitioners, decision-
makers, and policymakers. The approval
of a specific intervention can be nothing
else than a strong recommendation to
use the intervention. Nevertheless, with
the progress of the project, and once the
repository is populated sufficiently to be
useful for all major conditions, we could
expect that, at a country level, specific
policies could be elaborated in order to
promote the adoption of approved
interventions.
Conclusions
Prevention research has made consid-
erable methodological advances in the
past decades. This is not reflected in a
parallel improvement of practice, largely
due to a lack of regulatory systems for
transferring evidence into practice.
A possible exception is the Framework
Convention on Tobacco Control (www.
who.int/fctc), with which WHO produced
a strong frame of effective actions for
tobacco control. However, such a conven-
tion still remains an exception and can be
hardly expected to be reproduced for
other risk behaviours. The need to address
the overall deficit in rigorous evaluation of
prevention interventions for health-com-
promising behaviours is thus pressing in all
other fields of prevention in Europe and
beyond.
This paper aims to initiate a debate
about how best to develop a central,
transparent, public, and evidence-based
system of evaluation and approval of
prevention interventions for health-com-
promising behaviours in Europe. A four-
phase approval process is outlined and is
intended to foster further discussion.
This approval process would result in
a repository of effective prevention in-
terventions to be recommended to Eu-
ropean Union member states for adop-
tion, in order to base prevention
strategies on scientific evaluations. Poli-
cy-makers and people working in the
prevention field would find in this
repository interventions and programmes
to address the prevention needs of the
target populations, together with all
documents and materials useful to apply
them. Furthermore, the repository would
be even more useful for non-European
and developing countries having similar
health problems, for which the building
of any systematic evaluation system for
prevention is not foreseen for obvious
economic reasons.
To steer the evaluation activities of
prevention interventions in a transparent
approval system would be a great
progress not only for prevention practice
but also for prevention science: the
approval system would encourage evalu-
ation, without which an intervention
would not be included; would contribute
to the standardization of evaluation
methods; and would make available to
the scientific community all the reports
of the assessments, including component
evaluation and mediation analysis. This
could have the power to strongly im-
prove research and give a contribution
towards progressive learning on how
prevention works.
Finally, the supply of effective and
efficient behavioural interventions to pre-
vention practice and policy making, in
Europe but also elsewhere, would likely be
a cost-effective initiative with a large
expected impact on population health.
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